-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140

Benzinga·07/16/2026 12:01:59
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.